Skip to main content
SpringerLink
Log in

Cardiovascular Toxicity and Monitoring Methods in Oncologic Patients

  • Chapter
Imaging of Complications and Toxicity following Tumor Therapy

Part of the book series: Medical Radiology ((Med Radiol Diagn Imaging))

  • 777 Accesses

Abstract

Therapy of oncologic diseases requires a profound knowledge of the wide spectrum of available anticancer drugs and the ability of the oncologist to weigh the pros and cons of each medication in every single case individually to maintain a high standard of oncologic therapy.

Besides common side effects of anticancer drugs as headache, nausea, and diarrhea, adverse cardiovascular effects are, though less common, a crucial limitation with regard to the acceptance and continuation of the often long-standing therapy. Therefore, an appropriate choice of a single or multidrug medication, considering its special risks for cardiovascular side effects, is essential for preventing a preterm cancelation of a pivotal therapy.

This chapter offers an overview of widely used anticancer drugs, focusing on its certain cardiovascular effects, the possibility of cardioprotection, as well as important risk factors of treated patients, possibly boosting adverse cardiac effects.

Moreover, this chapter outlines commonly used monitoring methods for an appropriate surveillance, including those for high-risk oncologic patients with heart failure or arterial hypertension, and provides different treatment options in cases of manifest cardiovascular side effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

5-FU:

5-Fluorouracil

ACE:

Angiotensin-converting enzyme

BCR-ABL:

Break-point cluster-Abelson

BMI:

Body mass index

CHF:

Congestive heart failure

CML:

Chronic myeloid leukemia

CMR:

Cardiac magnetic resonance imaging

CRCD:

Chemotherapy-related cardiac dysfunction

ECE-1:

Endothelin-converting enzyme 1

ECG:

Electrocardiography

FDA:

Food and Drug Administration

GIST:

Gastrointestinal stromal tumor

HER2/erbB2:

Human epidermal growth factor receptor 2

HERA:

Herceptin adjuvant trial

LV:

Left ventricle

LVEF:

Left ventricular ejection fraction

NSCLC:

Non-small-cell lung carcinoma

NYHA:

New York Heart Association

PEG:

Polyethylene glycol

RR:

Relative risk

TDI:

Tissue Doppler imaging

TKI:

Tyrosine kinase inhibitor

VEGF:

Vascular endothelial growth factor

References

  • Abraham WT, Jessup M, Casey DE et al (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119:1977–2016

    Article  PubMed  Google Scholar 

  • Altena R, Perik PJ, van Veldhuisen DJ, de Vries EG, Gietema JA (2009) Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol 10(4):391–399

    Article  CAS  PubMed  Google Scholar 

  • Arbuck SG, Strauss H, Rowinsky E, Christian M, Suffness M, Adams J, et al (1993) A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr (15):117–130

    Google Scholar 

  • Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697

    Article  CAS  PubMed  Google Scholar 

  • Barrett-Lee PJ, Dixon JM, Farrell C et al (2009) Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk. Ann Oncol 20:816–827

    Article  CAS  PubMed  Google Scholar 

  • Becker K, Erkenbrecher JF, Haussinger D, Frieling T (1999) Cardiotoxicity of the antiproliferative compound fluorouracil. Drugs 57:475–484

    Article  CAS  PubMed  Google Scholar 

  • Bovelli D, Plataniotis G, Roila F, ESMO Guidelines Working Group (2010) Cardiotoxicity of chemotherapeutic agents and radio – therapy-related heart disease: ESMO Clinical Practice Guidelines. Ann Oncol 21:277–282

    Article  Google Scholar 

  • Bruder O, Wagner A, Jensen CJ, Schneider S, Ong P, Kispert E-M, Nassenstein K, Schlosser T, Sabin GV, Sechtem U, Mahrholdt H et al (2010) Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 56(11):875–87

    Google Scholar 

  • Buck T, Breithardt OA, Faber L et al (2009) Manual zur Indikation und Durchführung der Echokardiographie. Clin Res Cardiol Suppl 4(Suppl1):3–51

    Article  Google Scholar 

  • Cadeddu C, Piras A, Mantovani G et al (2010) Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160:487.e1–7

    Article  PubMed  Google Scholar 

  • Cardinale D, Sandri MT (2010) Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog Cardiovasc Dis 53:121–129

    Article  CAS  PubMed  Google Scholar 

  • Cardinale D, Sandri MT, Martinoni A et al (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36(2):517–522

    Article  CAS  PubMed  Google Scholar 

  • Cardinale D, Sandri MT, Colombo A et al (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 109:2749–2754

    Article  CAS  PubMed  Google Scholar 

  • Cardinale D, Colombo A, Sandri MT et al (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23):2474–2481

    Article  CAS  PubMed  Google Scholar 

  • Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G et al (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55:213–220

    Article  CAS  PubMed  Google Scholar 

  • Chen B, Peng X, Pentassuglia L, Lim CC, Sawyer DB (2007) Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 7:114–121

    Article  CAS  PubMed  Google Scholar 

  • Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L et al (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:2011–2019

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Collins C, Weiden PL (1987) Cardiotoxicity of 5-fluorouracil. Cancer Treat Rep 71:733–736

    CAS  PubMed  Google Scholar 

  • Crone SA, Zhao YY, Fan L, Gu Y, Minamisawa S, Liu Y et al (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8:459–465

    Article  CAS  PubMed  Google Scholar 

  • Cvetković RS, Scott LJ (2005) Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs 65:1005–1024

    Article  PubMed  Google Scholar 

  • Danilouchkine MG, Westenberg JM, De Roos A, Reiber JC et al (2005) Operator induced variability in cardiovascular MR: left ventricular measurements and their reproducibility. J Cardiovasc Magn Reson 7(2):447–457

    Article  PubMed  Google Scholar 

  • de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Piccart-Gebhart MJ, Suter TM (2014) Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial. J Clin Oncol 32(20):2159–2165

    Article  PubMed  Google Scholar 

  • de Forni M, Malet-Martino MC, Jaillais P, Shubinski RE, Bachaud JM, Lemaire L et al (1992) Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol 10:1795–1801

    PubMed  Google Scholar 

  • Di Lorenzo G, Autorino R, Bruni G, Carteni G, Ricevuto E, Tudini M, Ficorella C, Romano C, Aieta M, Giordano A et al (2009) Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 20:1535–1542

    Article  PubMed  Google Scholar 

  • Di Marco A, Cassinelli G, Arcamone F (1981) The discovery of daunorubicin. Cancer Treat Rep 65(Suppl 4):3–8

    PubMed  Google Scholar 

  • Early Breast Cancer Trialists’ Collaborative Group Ebctcg (2011) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379:432–444

    Article  Google Scholar 

  • Eidem BW (2008) Identification of anthracycline cardiotoxicity: left ventricular ejection fraction is not enough. J Am Soc Echocardiogr 21:1290–1292

    Article  PubMed  Google Scholar 

  • Eskilsson J, Albertsson M (1990) Failure of preventing 5-fluorouracil cardiotoxicity by prophylactic treatment with verapamil. Acta Oncol 29:1001–1003

    Article  CAS  PubMed  Google Scholar 

  • Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23:2900–2902

    Article  CAS  PubMed  Google Scholar 

  • Ewer MS, Vooletich MT, Durand JB et al (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23:820–7826

    Google Scholar 

  • Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS et al (2008) Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 10:5. doi:10.1186/1532-429X-10-5

  • Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick IDC, Singal PK et al (2011) The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 57(22):2263–2270

    Google Scholar 

  • Feldman AM, Lorell BH, Reis SE (2000) Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation 102(3):272–274

    Article  CAS  PubMed  Google Scholar 

  • Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676

    Article  CAS  PubMed  Google Scholar 

  • Ferrari R, Ceconi C, Campo G, Cangiano E, Cavazza C, Secchiero P et al (2009) Mechanisms of remodelling. Circ J 73:1973–1982

    Article  CAS  PubMed  Google Scholar 

  • Force T, Krause DS, Van Etten RA (2007) Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 7:332–344

    Article  CAS  PubMed  Google Scholar 

  • Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, White JA, Abdel-Aty H et al (2009) Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 53(17):1475–1487

    Google Scholar 

  • Gewirtz DA (1999) A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 57(7):727–741

    Article  CAS  PubMed  Google Scholar 

  • Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J (1981) Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 141:758–763

    Article  CAS  PubMed  Google Scholar 

  • Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25(4 Suppl 10):72–85

    CAS  PubMed  Google Scholar 

  • Grün S, Schumm J, Greulich S, Wagner A, Schneider S, Bruder O, Kispert E-M, Hill S, Ong P, Klingel K, Kandolf R, Sechtem U et al (2012) Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. J Am Coll Cardiol 59(18):1604–1615

    Google Scholar 

  • Hamed S, Barshack I, Luboshits G et al (2006) Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J 27:1876–1883

    Article  CAS  PubMed  Google Scholar 

  • Hare JL, Brown JK, Leano R, Jenkins C, Woodward N, Marwick TH (2009) Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. Am Heart J 158:294–301

    Article  CAS  PubMed  Google Scholar 

  • Harrigan CJ, Peters DC, Gibson CM, Maron BJ, Manning WJ, Maron MS, Appelbaum E et al (2011) Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology 258:128–133

    Article  PubMed  Google Scholar 

  • Hasinoff BB, Patel D (2010) Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib. Cardiovasc Toxicol 10:1–8

    Article  CAS  PubMed  Google Scholar 

  • Horacek JM, Jakl M, Horackova J, Pudil R, Jebavy L, Maly J (2009) Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Exp Oncol 31:115–117

    CAS  PubMed  Google Scholar 

  • Hudsmith L, Petersen S, Francis JM, Robson M, Neubauer S et al (2005) Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson 7:775–782

    Article  PubMed  Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  CAS  PubMed  Google Scholar 

  • Jensen SA, Sorensen JB (2006) Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. Cancer Chemother Pharmacol 58:487–493

    Article  CAS  PubMed  Google Scholar 

  • Joensuu H et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809–820

    Article  CAS  PubMed  Google Scholar 

  • Jurcut R, Wildiers H, Ganame J, D’hooge J, Paridaens R, Voigt JU (2008) Detection and monitoring of cardiotoxicity — what does modern cardiology offer? Support Care Cancer 16:437–445

    Article  PubMed  Google Scholar 

  • Kalay N, Basar E, Ozdogru I et al (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48:2258–2262

    Article  CAS  PubMed  Google Scholar 

  • Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh Y-T, Rosti G, Nakamae H, Gallagher NJ et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 12:841–851

    Article  CAS  PubMed  Google Scholar 

  • Keefe DL (2002) Trastuzumab-associated cardiotoxicity. Cancer 95:1592–1600

    Article  CAS  PubMed  Google Scholar 

  • Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C et al (2006) Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:908–916

    Article  PubMed  Google Scholar 

  • Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn JP, Klocke FJ, Judd RM et al (1999) Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 100(19):1992–2002

    Google Scholar 

  • Koh E, Nakamura T, Takahashi H (2004) Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats. Circ J 68:163–167

    Article  CAS  PubMed  Google Scholar 

  • Ku DD, Zaleski JK, Liu S, Brock TA (1993) Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol 265(2 Pt 2):H586–H592

    CAS  PubMed  Google Scholar 

  • Lestuzzi C, Crivellari D, Rigo F, Viel E, Meneguzzo N (2010) Capecitabine cardiac toxicity presenting as effort angina: a case report. J Cardiovasc Med (Hagerstown) 11:700–703

    Article  Google Scholar 

  • Lipshultz SE, Rifai N, Dalton VM et al (2004) The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 351(2):145–153

    Article  CAS  PubMed  Google Scholar 

  • Lipshultz SE, Scully RE, Lipsitz SR et al (2010) Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 11:950–961

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Loyola E, Sadana R, Stein C The European health report 2012: charting the way to well-being. WHO Library Cataloguing in Publication Data ISBN 978 92 890 14274

    Google Scholar 

  • Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505

    Article  CAS  PubMed  Google Scholar 

  • Lyu YL, Kerrigan JE, Lin CP, Azarva AM, Tsai YC, Ban Y et al (2007) Topoisomerase II beta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67(18):8839–8846

    Article  CAS  PubMed  Google Scholar 

  • Maceira AM, Prasad SK, Khan M, Pennell DJ et al (2006) Normalized left ventricular systolic and diastolic function by Steady State Free Precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson 8:417–426

    Article  CAS  PubMed  Google Scholar 

  • Maitland ML, Bakris GL, Black HR, Chen HX, Durand JB, Elliott WJ, Ivy SP, Leier CV, Lindenfeld J, Liu G et al (2010) Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J Natl Cancer Inst 102:596–604

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Marchandise B, Schroeder E, Bosly A et al (1989) Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 118:92–98

    Article  CAS  PubMed  Google Scholar 

  • Martin M, Esteva FJ, Alba E et al (2009) Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations. Oncologist 14:1–11

    Article  CAS  PubMed  Google Scholar 

  • Milan A, Puglisi E, Ferrari L, Bruno G, Losano I, Veglio F (2014) Arterial hypertension and cancer. Int J Cancer 134(10):2269–2277

    Article  CAS  PubMed  Google Scholar 

  • Mir O, Ropert S, Alexandre J, Goldwasser F (2009) Hypertension as a surrogate marker for the activity of anti-VEGF agents. Ann Oncol 20:967–970

    Article  CAS  PubMed  Google Scholar 

  • Miyagawa K, Emoto N, Widyantoro B et al (2010) Attenuation of doxorubicin-induced cardiomyopathy by endothelin-converting enzyme-1 ablation through prevention of mitochondrial biogenesis impairment. Hypertension 55:738–746

    Article  CAS  PubMed  Google Scholar 

  • Monreal M, Falga’ C, Valle R et al (2006) Venous thromboembolism in patients with renal insufficiency: findings from the RIETE registry. Am J Med 119:1073–1079

    Article  PubMed  Google Scholar 

  • Moore RA, Adel N, Riedel E et al (2011) High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 29:3466–3473

    Article  CAS  PubMed  Google Scholar 

  • Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S (2008) Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 300(19):2277–2285

    Article  CAS  PubMed  Google Scholar 

  • Neilan TG, Jassal DS, Scully MF et al (2006) Iloprost attenuates doxorubicin-induced cardiac injury in a murine model without compromising tumour suppression. Eur Heart J 27:1251–1256

    Article  CAS  PubMed  Google Scholar 

  • Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS (2008) Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83:679–686

    Article  PubMed  Google Scholar 

  • Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, Martino S, Mamounas EP, Kaufman PA, Wolmark N (2011) Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 29:3366–3373

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Popat S, Smith IE (2008) Therapy insight: anthracyclines and trastuzumab-the optimal management of cardiotoxic side effects. Nat Clin Pract Oncol 5(6):324–335

    CAS  PubMed  Google Scholar 

  • Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23:460–468

    Article  CAS  PubMed  Google Scholar 

  • Richards CJ, Je Y, Schutz FA, Heng DY, Dallabrida SM, Moslehi JJ, Choueiri TK (2011) Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib. J Clin Oncol 29:3450–3456

    Article  CAS  PubMed  Google Scholar 

  • Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK (2008) New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst 100:1058–1067

    Article  CAS  PubMed  Google Scholar 

  • Salvatorelli E, Menna P, Cascegna S, Liberi G, Calafiore AM, Gianni L et al (2006) Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther 318:424–433

    Article  CAS  PubMed  Google Scholar 

  • Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P et al (2005) N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 51:1405–1410

    Article  CAS  PubMed  Google Scholar 

  • Sawaya H, Sebag IA, Plana JC et al (2011) Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107:1375–1380

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Scully RE, Lipshultz SE (2007) Anthracycline cardiotoxicity in long-term survivors of childhood cancer. Cardiovasc Toxicol 7:122–128

    Article  CAS  PubMed  Google Scholar 

  • Sengupta PP, Northfelt DW, Gentile F et al (2008) Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin Proc 83:197–203

    Article  CAS  PubMed  Google Scholar 

  • Slordal L, Spigset O (2006) Heart failure induced by non-cardiac drugs. Drug Saf 29:567–586

    Article  PubMed  Google Scholar 

  • Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C et al (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25:3859–3865

    Article  CAS  PubMed  Google Scholar 

  • Swain SM, Vici P (2004) The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J Cancer Res Clin Oncol 130:1–7

    Article  CAS  PubMed  Google Scholar 

  • Taniguchi I (2005) Clinical significance of cyclophosphamide-induced cardiotoxicity. Intern Med 44:89–90

    Article  PubMed  Google Scholar 

  • Tassan-Mangina S, Codorean D, Metivier M et al (2006) Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr 7:141–146

    Article  PubMed  Google Scholar 

  • Todaro MC, Oreto L, Qamar R, Paterick TE, Carerj S, Khandheria BK (2013) Cardiooncology: state of the heart. Int J Cardiol 168:680–687

    Article  PubMed  Google Scholar 

  • Turrisi G, Montagnani F, Grotti S, Marinozzi C, Bolognese L, Fiorentini G (2010) Congestive heart failure during imatinib mesylate treatment. Int J Cardiol 145(1):148–150

    Article  PubMed  Google Scholar 

  • Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM (2010) Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 15:130–141

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Van Dalen EC, Michiels EM, Caron HN, Kremer LC (2010) Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev (3):CD005006

    Google Scholar 

  • Van Dalen EC, Caron HN, Dickinson HO, Kremer LC (2011) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev (6):CD003917

    Google Scholar 

  • Von Hoff DD, Layard MW, Basa P et al (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91(5):710–717

    Article  Google Scholar 

  • Wang J, Khoury DS, Thohan V et al (2007) Global diastolic strain rate for the assessment of left ventricular relaxation and filling pressures. Circulation 115:1376–1383

    Article  PubMed  Google Scholar 

  • Wassmuth R, Lentzsch S, Erdbruegger U, Schulz-Menger J, Doerken B, Dietz R, Friedrich MG et al (2001) Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging-A pilot study. Am Heart J 141:1007–1013

    Article  CAS  PubMed  Google Scholar 

  • Wu S, Chen JJ, Kudelka A, Lu J, Zhu X (2008a) Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol 9(2):117–123

    Google Scholar 

  • Wu E, Ortiz JT, Tejedor P, Lee DC, Bucciarelli-Ducci C, Kansal P, Carr JC, Holly TA, Lloyd-Jones D, Klocke FJ et al (2008b) Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or endsystolic volume index: prospective cohort study. Heart 94(6):730–736

    Google Scholar 

  • Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231–2247

    Article  CAS  PubMed  Google Scholar 

  • Yeh ET, Tong AT, Lenihan DJ et al (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109:3122–3131

    Article  PubMed  Google Scholar 

  • Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, Marchionni MA et al (1998) Neuregulins promote survival and growth of cardiac myocytes: persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273:10261–10269

    Article  CAS  PubMed  Google Scholar 

  • Zhu X, Stergiopoulos K, Wu S (2009) Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol 48:9–17

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diagnostic and Interventional Radiology, Center for Radiology and Endoscopy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Maxim Avanesov & Gunnar K. Lund

  2. Department of Internal Medicine II and Clinic (Oncology Center), Center for Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Andreas Block

Authors
  1. Maxim Avanesov
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andreas Block
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gunnar K. Lund
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maxim Avanesov .

Editor information

Editors and Affiliations

  1. Dept. of Radiology, University Hospital Heidelberg, Heidelberg, Germany

    Hans-Ulrich Kauczor

  2. Institute of Radiology, University Hospital Erlangen, Erlangen, Germany

    Tobias Bäuerle

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Avanesov, M., Block, A., Lund, G.K. (2015). Cardiovascular Toxicity and Monitoring Methods in Oncologic Patients. In: Kauczor, HU., Bäuerle, T. (eds) Imaging of Complications and Toxicity following Tumor Therapy. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/174_2015_1053

Download citation

  • DOI: https://doi.org/10.1007/174_2015_1053

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12840-5

  • Online ISBN: 978-3-319-12841-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation